RNASE3

Across TCGA pan-cancer cohorts, RNASE3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RNASE3 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RNASE3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RNASE3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where RNASE3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.347	0.829	.006	15	view →
HNSC	OS	Tertile	All	0.845	0.626	.016	12	view →
LUAD	OS	Quartile	All	0.770	0.940	.015	8	view →
UCEC	OS	Tertile	II,III,IV	1.000	0.665	.038	4	view →
GBM	DFS	Tertile	All	0.612	0.846	.025	2	view →
CCRCC	DFS	Quartile	III,IV	0.412	0.863	.018	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RNASE3–PDAC (OS)

Open the PDAC breakdown →